research communications
Re-refinement of Plasmodium falciparum orotidine 5′-monophosphate decarboxylase provides a clearer picture of an important malarial drug target
aChemistry Department, Wabash College, 301 West Wabash Avenue, Crawfordsville, IN 47933, USA, and bChemistry Department, Franklin and Marshall College, PO Box 3003, Lancaster, PA 17604, USA
*Correspondence e-mail: gbrandt@fandm.edu
The development of antimalarial drugs remains a public health priority, and the orotidine 5′-monophosphate decarboxylase from Plasmodium falciparum (PfOMPDC) has great potential as a drug target. The crystallization of PfOMPDC with substrate bound represents an important advance for structure-based drug-design efforts [Tokuoka et al. (2008), J. Biochem. 143, 69–78]. The complex of the enzyme bound to the substrate OMP (PDB entry 2za1) would be of particular utility in this regard. However, re-refinement of this structure of the Michaelis complex shows that the bound ligand is the product rather than the substrate. Here, the re-refinement of a set of three structures, the apo enzyme and two versions of the product-bound form (PDB entries 2za1, 2za2 and 2za3), is reported. The improved geometry and fit of these structures to the observed electron density will enhance their utility in antimalarial drug design.
Keywords: orotidine 5′-monophosphate decarboxylase; Plasmodium falciparum; Michaelis complex; re-refinement.
PDB references: orotidine 5'-monophosphate decarboxylase, 6dsq; 6dsr; 6dss
1. Introduction
Protein structures, particularly those with substrates bound, have been invaluable in helping to illuminate the details of enzyme mechanisms and the design of novel inhibitors (Petsko & Ringe, 2004). In order to provide insight into the workings of enzymes, protein structures must be interpreted in the light of, and are limited by, their ability to capture atomic-level detail (Wlodawer et al., 2018). The enzyme orotidine 5′-monophosphate decarboxylase (OMPDC) is involved in the synthesis of pyrimidine and is essential in malaria parasites (Rathod & Reyes, 1983). Unlike their human hosts, who have a salvage pathway, malaria parasites rely entirely on de novo nucleotide synthesis, so OMPDC has been proposed as a potential therapeutic target (Cassera et al., 2011). In addition, the ability of OMPDC to efficiently catalyze decarboxylation without a cofactor has attracted the interest of mechanistic enzymologists (Richard et al., 2018; Lewis et al., 2017; Reyes et al., 2015; Vardi-Kilshtain et al., 2013; Lee & Houk, 1997). For both of these reasons, the structure of OMPDC from Plasmodium falciparum (PfOMPDC) with the substrate orotidine 5′-monophosphate (OMP) bound would be of considerable scientific interest. The series of structures with PDB codes 2za2, 2za1 and 2za3 represents an attempt to capture the enzyme alone, with the OMP substrate and with its product uridine 5′-monophosphate (UMP), respectively (Tokuoka et al., 2008).
Inspection of these models reveals significant imperfections in terms of backbone geometry, density fit and ligand selection (Table 1). The PDB-REDO server is often able to make dramatic improvements to problematic structures in an automated fashion (Joosten et al., 2014). However, in the case of these three structures, PDB-REDO was unable to improve the models to current standards of practice. Here, we describe the re-refinement of PDB entries 2za1, 2za2 and 2za3, resulting in a dramatic improvement of the models as suggested by the geometric parameters, density-fit analysis and R factors (Table 1). Our most consequential finding is that re-refinement of 2za1 shows that the bound ligand is actually the product UMP, rather than the substrate OMP as reported (Tokuoka et al., 2008). These re-refined structures have been deposited in the PDB as entries 6dsq, 6dsr and 6dss, respectively.
|
2. Materials and methods
2.1. Structure solution and refinement
All three structures were re-refined from the deposited structure factors using the PHENIX suite (Adams et al., 2010). A starting model of the apoenzyme PfOMPDC (PDB entry 3n3m; Y. Liu, L. P. Kotra & E. F. Pai, unpublished work) was used to generate a molecular-replacement solution. In order to minimize model bias, was carried out after randomization of the coordinates of the input model in all cases using the `shake' feature in phenix.pdbtools (Adams et al., 2010) with a maximum displacement of 0.2 Å. Coordinate randomization was accompanied by the removal of all ligands and bound water molecules to produce OMIT maps of bound ligands. Structures were validated using MolProbity and, during deposition, by the wwPDB validation service (Williams et al., 2018; Chen et al., 2010). The final re-refined structure with UMP bound in the active site of PfOMPDC was refined using REFMAC and BUSTER-TNT (Murshudov et al., 2011; Blanc et al., 2004). For comparison, electron-density maps of the deposited 2za1 structure were also generated using PHENIX, REFMAC and BUSTER-TNT. In both cases, all three programs gave consistent results. Figs. 1, 2(b), 2(c) and 3 were generated from the electron-density maps produced by in PHENIX using UCSF Chimera (Pettersen et al., 2004).
3. Results and discussion
Re-assessment of the structure of the orotidine 5′-monophosphate decarboxylase (OMPDC) from P. falciparum with substrate bound has revealed that this structure is not the Michaelis complex, as reported, but rather a product complex. The structural enzymology of OMPDC has depended on high-quality structures of intermediates in the active site (Richard et al., 2018; Lewis et al., 2017; Reyes et al., 2015; Vardi-Kilshtain et al., 2013; Lee & Houk, 1997). Additionally, the structure of OMPDC from P. falciparum is important because of its potential as drug target (Tokuoka et al., 2008; Fujihashi et al., 2015; Cassera et al., 2011). The presence of bound substrates in the study of Tokuoka and coworkers enhances the value of these structures to structure-based drug design (Tokuoka et al., 2008). Indeed, in silico drug-design efforts based on these structures have been reported (Takashima et al., 2012; Drinkwater & McGowan, 2014). For both of these reasons, it is important that these structures are well determined and that the ligands are correctly identified (Touw et al., 2016).
The enzyme OMPDC is a member of the (β/α)8-barrel superfamily. The P. falciparum OMPDC structures reported by Tokuoka and coworkers maintain this fold (Fig. 1).
However, the three structures of the set are not well validated overall (Wlodawer et al., 2018; Dauter et al., 2014; Kleywegt & Jones, 1996). By both clashscore and number of Ramachandran outliers, the OMP-bound structure with PDB code 2za1, in particular, is seen to be among the lowest scoring in the PDB (12th percentile). The re-refinement reported here solves these overall problems (Table 1, Fig. 2a). The number of residues in disfavored regions of the Ramachandran plot is reduced to an appropriate level, and the overall clashscores improve to the very topmost percentile of structures in the PDB (Fig. 2a). A specific example of the results of these improvements can be seen in Fig. 2(b), where a region of the protein that was formerly fitted as an extended loop because of a residue in a disallowed conformation is shown to form a proper α-helix once the residue is modeled with allowed Ramachandran angles. The potential importance of the refitting to the active site is shown in Fig. 2(c), which depicts the backbone atoms in the apoenzyme that are within 5 Å of where the substrate would bind. Although the original and refitted structures agree overall, regions of difference that affect the shape of the substrate-binding pocket can be observed.
More so than the global structure, modeling of the ligand in these structures is, of course, critical to their interpretation. From an enzymological perspective, the decarboxylation reaction catalyzed by OMPDC is a very well studied example of the rate acceleration that can arise from control of the electrostatic environment around a substrate (Fried & Boxer, 2017; Amyes et al., 2017; Jordan & Patel, 2013). OMPDC has been shown to convert substrate to product with minimal active-site rearrangement (Richard et al., 2018; Fried & Boxer, 2017). This aspect of the enzyme is important because the experimental method of Tokuoka and coworkers for forming the co-complex of the enzyme and substrate relied on soaking the crystals in OMP. The turnover rate of the wild-type enzyme is very high, and catalysis is thought to occur with little rearrangement of the active site (Fujihashi et al., 2013; Wu et al., 2000). Little barrier exists to the enzyme simply converting the substrate in these soaking experiments to product. Indeed, the originally deposited 2za1 structure itself gives evidence that the substrate OMP is an imperfect fit to the observed electron density. The B factors of the carboxylate atoms are significantly higher than those of the uridine, particularly in the B subunit (average carboxylate B factor of 109 Å2 compared with 73 Å2 for the rest of the OMP cofactor). Another noteworthy aspect of modeling the carboxylate into this electron density is that the interatomic distances between the OMP carboxylate O atom and the nearest Asp136 carboxylate O atom are 2.3 and 2.5 Å in the A and B subunits, respectively. This proximity was interpreted as evidence of the mechanistic role of electrostatic destabilization of the substrate carboxylate on the part of the enzyme (Tokuoka et al., 2008). A more parsimonious explanation, perhaps, is that the substrate carboxylate is not present in this space.
The validation metrics of the original structures raise the possibility that model bias has not been well controlled in these structures (Hodel et al., 1992). In fact, the relatively large gap observed between Rcryst and Rfree for all three structures is a sign of overfitting (Kleywegt & Jones, 1997). Model bias is a special concern when it comes to ligand fitting (Wlodawer et al., 2018). Unbiased re-refinement of PDB entry 2za1 shows that the OMIT map for the bound ligand contains very little electron density in the region of the carboxylate (Fig. 3a). The placement of UMP into this electron density and subsequent confirms that no positive difference density exists in the carboxylate region (Fig. 3b). Finally, attempting to fit OMP into this electron density reveals the extent of negative difference density around these atoms (Fig. 3c). To be sure that the observed differences in electron density around the orotidine carboxylate were not owing to idiosyncrasies of the software, both the originally deposited structure 2za1 and the re-refined structure 6dsq were evaluated using REFMAC and BUSTER-TNT to complement the PHENIX All three programs revealed pronounced negative difference density around the carboxylate in PDB entry 2za1, suggesting its absence. At the same time, all three packages showed that UMP fits well into the observed electron density, without any positive difference density, in the absence of the carboxylate. Therefore, we conclude that it is the reaction product UMP and not the substrate OMP that is bound in PDB entry 2za1.
Indeed, this conclusion is consistent with the thorough reporting of Tokuoka and coworkers of the differences among the three structures, in which the two ligand-bound structures 2za1 and 2za3 are seen to be essentially identical, differing in the same ways from the apo structure 2za2.
Funding information
We acknowledge the support of Wabash College and the Haines Biochemistry Fund (WRPN and KHJW), and Franklin and Marshall College's Leser and Hackman Funds (GSB and LMDK).
References
Adams, P. D. et al. (2010). Acta Cryst. D66, 213–221. Web of Science CrossRef CAS IUCr Journals Google Scholar
Amyes, T. L., Malabanan, M. M., Zhai, X., Reyes, A. C. & Richard, J. P. (2017). Protein Eng. Des. Sel. 30, 157–165. CrossRef Google Scholar
Blanc, E., Roversi, P., Vonrhein, C., Flensburg, C., Lea, S. M. & Bricogne, G. (2004). Acta Cryst. D60, 2210–2221. Web of Science CrossRef CAS IUCr Journals Google Scholar
Cassera, M. B., Zhang, Y., Hazleton, K. Z. & Schramm, V. L. (2011). Curr. Top. Med. Chem. 11, 2103–2115. Google Scholar
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S. & Richardson, D. C. (2010). Acta Cryst. D66, 12–21. Web of Science CrossRef CAS IUCr Journals Google Scholar
Dauter, Z., Wlodawer, A., Minor, W., Jaskolski, M. & Rupp, B. (2014). IUCrJ, 1, 179–193. Web of Science CrossRef CAS PubMed IUCr Journals Google Scholar
Drinkwater, N. & McGowan, S. (2014). Biochem. J. 461, 349–369. CrossRef Google Scholar
Fried, S. D. & Boxer, S. G. (2017). Annu. Rev. Biochem. 86, 387–415. CrossRef Google Scholar
Fujihashi, M., Ishida, T., Kuroda, S., Kotra, L. P., Pai, E. F. & Miki, K. (2013). J. Am. Chem. Soc. 135, 17432–17443. CrossRef Google Scholar
Fujihashi, M., Mnpotra, J. S., Mishra, R. K., Pai, E. F. & Kotra, L. P. (2015). J. Genet. Genomics, 42, 221–234. CrossRef Google Scholar
Hodel, A., Kim, S.-H. & Brünger, A. T. (1992). Acta Cryst. A48, 851–858. CrossRef CAS Web of Science IUCr Journals Google Scholar
Joosten, R. P., Long, F., Murshudov, G. N. & Perrakis, A. (2014). IUCrJ, 1, 213–220. Web of Science CrossRef CAS PubMed IUCr Journals Google Scholar
Jordan, F. & Patel, H. (2013). ACS Catal. 3, 1601–1617. CrossRef Google Scholar
Kleywegt, G. J. & Jones, T. A. (1996). Structure, 4, 1395–1400. CrossRef CAS PubMed Web of Science Google Scholar
Kleywegt, G. J. & Jones, T. A. (1997). Methods Enzymol. 277, 208–230. CrossRef PubMed CAS Web of Science Google Scholar
Lee, J. K. & Houk, K. N. (1997). Science, 276, 942–945. CrossRef CAS PubMed Google Scholar
Lewis, C. A., Shen, L., Yang, W. & Wolfenden, R. (2017). Biochemistry, 56, 1498–1503. CrossRef Google Scholar
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M. D., Long, F. & Vagin, A. A. (2011). Acta Cryst. D67, 355–367. Web of Science CrossRef CAS IUCr Journals Google Scholar
Petsko, G. A. & Ringe, D. (2004). Protein Structure and Function. London: New Science Press. Google Scholar
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C. & Ferrin, T. E. (2004). J. Comput. Chem. 25, 1605–1612. Web of Science CrossRef PubMed CAS Google Scholar
Rathod, P. K. & Reyes, P. (1983). J. Biol. Chem. 258, 2852–2855. CAS PubMed Web of Science Google Scholar
Reyes, A. C., Zhai, X., Morgan, K. T., Reinhardt, C. J., Amyes, T. L. & Richard, J. P. (2015). J. Am. Chem. Soc. 137, 1372–1382. CrossRef Google Scholar
Richard, J. P., Amyes, T. L. & Reyes, A. C. (2018). Acc. Chem. Res. 51, 960–969. CrossRef Google Scholar
Takashima, Y., Mizohata, E., Krungkrai, S. R., Fukunishi, Y., Kinoshita, T., Sakata, T., Matsumura, H., Krungkrai, J., Horii, T. & Inoue, T. (2012). J. Biochem. 152, 133–138. CrossRef Google Scholar
Tokuoka, K., Kusakari, Y., Krungkrai, S. R., Matsumura, H., Kai, Y., Krungkrai, J., Horii, T. & Inoue, T. (2008). J. Biochem. 143, 69–78. CrossRef Google Scholar
Touw, W. G., Joosten, R. P. & Vriend, G. (2016). J. Mol. Biol. 428, 1375–1393. Web of Science CrossRef CAS PubMed Google Scholar
Vardi-Kilshtain, A., Doron, D. & Major, D. T. (2013). Biochemistry, 52, 4382–4390. Google Scholar
Williams, C. J. et al. (2018). Protein Sci. 27, 293–315. CrossRef Google Scholar
Wlodawer, A., Dauter, Z., Porebski, P. J., Minor, W., Stanfield, R., Jaskolski, M., Pozharski, E., Weichenberger, C. X. & Rupp, B. (2018). FEBS J. 285, 444–466. Web of Science CrossRef Google Scholar
Wu, N., Mo, Y., Gao, J. & Pai, E. F. (2000). Proc. Natl Acad. Sci. USA, 97, 2017–2022. Web of Science CrossRef PubMed CAS Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.